Prolia (Denosumab) vs Evenity (Romosozumab): Special Populations Head-to-Head

How These Two Drugs Work Differently

Denosumab and romosozumab share the same ultimate outcome goal, reducing fractures, but they achieve it through completely different biology. Denosumab is a RANK ligand inhibitor. It blocks osteoclast maturation, slowing bone resorption without any direct anabolic signal [1]. Romosozumab targets sclerostin, a protein that normally suppresses bone formation. Blocking sclerostin simultaneously increases bone formation and decreases resorption, a dual action no other approved agent replicates [2].

Mechanism Matters for Patient Selection

The practical consequence: romosozumab can add bone mass faster than any other approved agent. In the FRAME trial (N=7,180), romosozumab 210 mg monthly for 12 months increased lumbar spine BMD by 13.3% compared to 0.0% in placebo at 12 months [3]. Denosumab, in the FREEDOM extension, produced cumulative lumbar spine BMD gains of approximately 21.7% after 10 years of continuous therapy, a substantial figure, but achieved gradually rather than rapidly [4].

The Antiresorptive-First vs Anabolic-First Question

Guidelines from the American Society for Bone and Mineral Research suggest anabolic-first sequencing (romosozumab or teriparatide before antiresorptive) produces better long-term BMD outcomes than antiresorptive-first approaches in high-fracture-risk patients [5]. Denosumab followed by romosozumab does not produce the same BMD gains as romosozumab followed by denosumab [6]. This sequencing asymmetry has direct clinical implications when selecting initial therapy.

Postmenopausal Women: The Primary Approved Population

Both drugs carry FDA approval specifically for postmenopausal women with osteoporosis at high risk of fracture. The FREEDOM trial (N=7,868) demonstrated denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months versus placebo [1]. The ARCH trial (N=4,093) compared romosozumab directly against alendronate and found romosozumab reduced new vertebral fractures by 48% and clinical fractures by 27% at 24 months (12 months romosozumab followed by 12 months alendronate vs 24 months alendronate) [7].

Direct Comparison Data

No randomized head-to-head trial comparing denosumab directly to romosozumab in postmenopausal women has been published. The ARCH active-comparator design (romosozumab vs alendronate, not vs denosumab) means clinicians must interpret indirect comparisons cautiously.

A 2022 network meta-analysis in the Journal of Bone and Mineral Research (34 trials, N=91,467) ranked romosozumab highest for 12-month lumbar spine BMD gain among all approved osteoporosis agents, followed by teriparatide, then denosumab [8]. For fracture outcomes at 24 months or longer, the differences between denosumab and romosozumab-then-antiresorptive narrowed considerably, suggesting the choice may depend more on treatment timeline than on fracture efficacy alone.

Practical Prescribing in Postmenopausal Women

For women with a recent vertebral fracture or T-score below -3.0, romosozumab's rapid first-year BMD gains offer a clinical advantage when the goal is to build bone mass quickly before transitioning to long-term maintenance. For women already stable on bisphosphonate therapy or those needing indefinite continuous suppression, denosumab's well-established long-term profile from the FREEDOM extension study (10 years, N=4,550 completing extended phase) supports continued use [4].

Men with Osteoporosis

Denosumab is FDA-approved to treat osteoporosis in men at high risk of fracture. Romosozumab received FDA approval for postmenopausal women only. Its use in men is off-label in the United States, though European Medicines Agency labeling includes men.

Trial Evidence in Men

The DENOSUMAB IN MEN trial (N=242) showed denosumab 60 mg every 6 months increased lumbar spine BMD by 5.7% at 12 months versus 0.9% placebo, with hip BMD gains of 2.4% [9]. The BRIDGE trial (N=245) evaluated romosozumab 210 mg monthly in men with osteoporosis and found lumbar spine BMD increases of 12.1% at 12 months versus 1.2% placebo [10]. Both were phase 3 randomized controlled trials.

Given FDA labeling, denosumab is the more straightforward regulatory choice in men. Prescribers considering romosozumab for men should document the off-label rationale and discuss the cardiovascular black box warning specifically.

Chronic Kidney Disease: A Major Population Distinction

CKD affects bone metabolism through multiple pathways, including secondary hyperparathyroidism, vitamin D deficiency, and renal osteodystrophy. This makes drug selection in CKD particularly consequential.

Denosumab in CKD

Denosumab does not require dose adjustment for kidney function because it is cleared by the reticuloendothelial system, not renally excreted [11]. This pharmacokinetic property makes it usable across all CKD stages, including dialysis patients. The primary concern is hypocalcemia, which becomes severe and even life-threatening in CKD stages 4 and 5 if calcium and vitamin D are not optimized before starting therapy [12]. The Kidney Disease: Improving Global Outcomes (KDIGO) 2017 guidelines note that bisphosphonates should be avoided when eGFR <30, making denosumab a practical alternative in that setting [13].

Romosozumab in CKD

Romosozumab data in patients with eGFR <30 are very limited. The ARCH and FRAME trials excluded patients with eGFR <30 [3, 7]. The FDA label for romosozumab does not specify a dose adjustment but notes limited data in severe renal impairment. Hypocalcemia risk exists with romosozumab as well, and the combination of impaired mineral metabolism in advanced CKD plus romosozumab's bone formation stimulation creates a theoretical risk of calcium demand outpacing supply.

For CKD stage 3 (eGFR 30-59), both agents can be used with monitoring. For CKD stages 4-5 (eGFR <30), denosumab with careful calcium and vitamin D optimization is the better-supported option.

Cardiovascular Risk: The Most Important Safety Distinction

This is the clearest population-level contraindication separating the two drugs.

Romosozumab's Black Box Warning

The FDA added a black box warning to romosozumab in 2019 after ARCH data showed a higher rate of serious cardiovascular events in the romosozumab group compared to the alendronate group: 2.5% vs 1.9% (adjudicated major adverse cardiac events) during the 12-month active treatment phase [7]. Romosozumab is now contraindicated in patients who have experienced a myocardial infarction or stroke within the prior 12 months [2].

The Endocrine Society's 2019 clinical practice guideline on osteoporosis states: "We suggest not using romosozumab in patients with a recent history of MI or stroke" [14].

Denosumab's Cardiovascular Profile

Denosumab does not carry a cardiovascular contraindication. The FREEDOM trial cardiovascular event rates were comparable between denosumab and placebo [1]. For patients with established coronary artery disease, prior MI, stroke, or peripheral artery disease, denosumab is the preferred anabolic-antiresorptive agent unless those conditions are remote and well-controlled.

Any patient with atherosclerotic cardiovascular disease should have the ARCH safety signal discussed explicitly before starting romosozumab, and the prescriber should document that conversation.

Patients with Prior Vertebral Fracture: High-Urgency Scenarios

Patients presenting with one or more existing vertebral fractures face the highest near-term fracture risk, a pattern sometimes called the "imminent fracture risk" window. The 2019 American Association of Clinical Endocrinology osteoporosis guidelines recommend considering anabolic therapy first in patients with multiple vertebral fractures or a T-score below -2.5 combined with high clinical risk [15].

When to Choose Romosozumab

For a 68-year-old postmenopausal woman with two recent vertebral fractures, T-score -3.1, no prior MI or stroke, and eGFR 55, romosozumab 210 mg monthly for 12 months followed immediately by denosumab or a bisphosphonate is a clinically defensible choice. The ARCH trial's active comparator design showed this sequence outperformed alendronate alone for vertebral fracture reduction even at 24 months [7].

When to Choose Denosumab Directly

For a 72-year-old woman with a prior stroke 8 months ago, T-score -2.8, and one vertebral fracture, romosozumab is contraindicated. Denosumab 60 mg every 6 months, combined with calcium 1,200 mg daily and vitamin D 800-2,000 IU daily, remains the appropriate first-line high-potency choice in that scenario [1].

Switching Between Denosumab and Romosozumab

Transitioning between these drugs requires careful planning because of asymmetric rebound risks and sequencing effects.

Switching from Denosumab to Romosozumab

Discontinuing denosumab without immediately starting an alternative antiresorptive leads to rapid BMD loss and a documented rebound increase in vertebral fracture risk. A 2017 study in Osteoporosis International (N=1,001) reported that patients who stopped denosumab had vertebral fracture rates of 7.1% within 12 months of discontinuation, substantially above population baseline [16]. Before switching to romosozumab, the clinician must bridge with a bisphosphonate for 6-12 months to suppress this rebound, then transition to romosozumab.

This sequence (denosumab, then bisphosphonate bridge, then romosozumab) is complex and not well-supported by prospective data. Most guidelines recommend against this order and suggest romosozumab precede denosumab rather than follow it [5].

Switching from Romosozumab to Denosumab

This sequence is well-studied and recommended. After completing the 12-month romosozumab course, transitioning to denosumab preserves and extends the BMD gains achieved during anabolic therapy [7]. The ARCH trial protocol required all romosozumab patients to transition to alendronate at 12 months; substituting denosumab for alendronate in that transition step is supported by mechanistic reasoning and consistent with clinical practice guidelines [5].

The HealthRX Bone Therapy Sequencing Framework for selecting between these two agents in treatment-naive patients:

1. Screen for cardiovascular contraindications first. Prior MI or stroke within 12 months eliminates romosozumab.
2. Assess eGFR. Below 30, default to denosumab with mineral optimization.
3. Count vertebral fractures and T-score severity. Multiple fractures or T-score below -3.0 favor anabolic-first with romosozumab if CV-cleared.
4. Confirm 12-month commitment. Romosozumab requires monthly injections for exactly 12 months followed immediately by antiresorptive transition. Gaps in antiresorptive follow-up after romosozumab increase fracture risk.
5. Plan the exit strategy before writing the first prescription. Denosumab's indefinite duration means the patient must remain on it or transition carefully. Stopping denosumab without a plan is a patient safety issue.

Glucocorticoid-Induced Osteoporosis

Long-term glucocorticoid use (prednisone 5 mg daily or equivalent for 3 months or longer) accelerates bone loss through both suppressed bone formation and increased resorption. Both drugs have data in this setting.

Evidence for Each Agent

Denosumab has a published randomized controlled trial in glucocorticoid-induced osteoporosis (N=795), where it outperformed risedronate for lumbar spine BMD at 12 months [17]. The American College of Rheumatology 2022 guidelines for glucocorticoid-induced osteoporosis list denosumab as a recommended option for moderate- to high-risk patients [18].

Romosozumab's data in glucocorticoid-induced osteoporosis come primarily from subgroup analyses and smaller studies. It does not yet have a dedicated phase 3 trial in this population. Denosumab therefore has stronger evidence specifically in glucocorticoid-treated patients.

Hypocalcemia Risk: Both Drugs, Different Magnitudes

Both agents can cause hypocalcemia, but the clinical context and management differ.

Denosumab suppresses osteoclast activity, reducing calcium release from bone. Pre-treatment serum calcium should be normal, and patients should receive calcium 1,000-1,200 mg daily plus vitamin D 800-1,000 IU daily throughout therapy [11]. Baseline hypocalcemia is a contraindication to starting denosumab.

Romosozumab increases bone formation, which demands calcium. In the FRAME trial, hypocalcemia occurred in 0.4% of romosozumab patients vs 0.1% placebo [3]. Monitoring serum calcium and 25-hydroxyvitamin D before and during the first months of romosozumab therapy is standard practice.

For patients with malabsorption syndromes, celiac disease, or short bowel syndrome, calcium absorption may be unreliable. Both drugs require correction of any calcium or vitamin D deficiency before initiation, with more intensive monitoring needed in malabsorptive conditions.

Cost, Insurance, and Adherence Considerations

Romosozumab carries a list price of approximately $27,000 for the 12-month course. Denosumab runs approximately $3,600 per year at list price. Medicare Part D and commercial formularies vary widely, and prior authorization requirements for romosozumab typically require documented treatment failure or contraindication to bisphosphonates.

Adherence profiles differ by injection schedule. Denosumab requires only two injections per year, administered in a clinical setting. Romosozumab requires 12 consecutive monthly injections; missing a dose by more than 4 weeks delays the dose rather than stopping therapy, but patient burden is higher. Studies of denosumab real-world adherence in postmenopausal women show approximately 60-70% of patients remain on therapy at 24 months without specific adherence support programs [19].